Jonathan Goldin

Jonathan Goldin is Professor and Department Chair of Radiological Sciences at the University of California Los Angeles (UCLA) School of Medicine, where he also holds a professorship in the Department of Medicine. He holds the prestigious Leo G. Rigler Chair in Radiological Sciences, reflecting his significant contributions to the field. Dr. Goldin is a leading expert in quantitative imaging analysis with a focus on pulmonary diseases.

Dr. Goldin's research primarily centers on quantitative CT imaging analysis for pulmonary conditions, particularly interstitial lung disease and emphysema. His work bridges radiology, pulmonology, and computer science, developing innovative methods to quantify disease severity and predict treatment response. He has pioneered techniques for assessing lung fibrosis, emphysema, and airway disease through advanced image analysis, creating objective biomarkers that support clinical decision-making and therapeutic development. His research has significant implications for clinical trials methodology and personalized medicine approaches in pulmonary disease management.

Analysis of Dr. Goldin's extensive publication record reveals a consistent focus on quantitative imaging biomarkers for pulmonary diseases, with particular emphasis on interstitial lung disease and emphysema. His work demonstrates a progression from foundational imaging techniques to sophisticated AI-driven analysis methods. The publications show increasing integration of machine learning approaches with traditional radiological assessment, reflecting broader trends in medical imaging. A notable theme across his work is the translation of quantitative imaging findings into clinically meaningful metrics that can guide treatment decisions and predict outcomes.

• Leo G. Rigler Chair in Radiological Sciences

Dr. Goldin has secured substantial research funding from the National Institutes of Health, including as Principal Investigator for the Alveolitis and Fibrosis in Scleroderma Lung Disease study (R01HL072424), and as Co-Principal Investigator for the Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection (R01HL153964) and Quantitative CT Imaging for Response Assessment when using Dose Reduction Methods (U01CA181156). His research program demonstrates sustained funding and significant contributions to the field of quantitative pulmonary imaging.